On October 18, the Indonesian Center for the Phase III clinical trial of the novel coronavirus mna vaccine (awcorna), which is co-sponsored by Yuxi Watson Biotechnology Co., Ltd., Yunnan Watson Biotechnology Co., Ltd. and Suzhou Aibo Biotechnology Co., Ltd., has completed the first case of subject enrollment, and the trial plans to enroll at least 3,000 subjects in Indonesia.
It is understood that in early October, 4 members of the Watson Biological Expatriate Clinical Team have arrived in Jakarta, Indonesia, and after completing the 8-day isolation in accordance with the local epidemic prevention policy, they will work with local investigators and cro teams (contract research organizations) to participate in clinical trial site training, preparation and subject recruitment.
In addition to sending clinical team members, Watson Biotech has another 4 expatriate technical cooperation members who arrived in Jakarta at the same time, and is currently carrying out technical cooperation related work with local partners in Indonesia.
In addition, the Phase III clinical trial of the vaccine mexico center has started the vaccination of subjects at the end of September, and the work is currently being carried out in an orderly manner.
With the initiation and advancement of Phase III clinical trials in overseas national centers, the vaccine is expected to obtain the results of the first protective efficacy evaluation from the end of 2021 to the beginning of 2022 to support the marketing application and approval of the vaccine at home and abroad. (Feifei Yan)
![Explosive melon, the richest man quietly built a warehouse Watson creature, pay close attention to the melon of the possible more preemptive Watson creatures a brain hole[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)